Global /China /Healthcare /Drug Manufacturers - General /003020
chevron_leftBack
Hefei Lifeon Pharmaceutical Co., Ltd. logo

Hefei Lifeon Pharmaceutical Co., Ltd.

003020
SHE: 003020 Delayed
22.73CNY -0.7%
3.36 USD
As of 14 June 2026, Hefei Lifeon Pharmaceutical Co., Ltd. has a market cap of $637.96M USD, ranking #13525 globally and #4111 in China. It ranks #1215 in the Healthcare sector, and #451 in the Drug Manufacturers - General industry.
Global Rank
13525
Country Rank
4111
Sector Rank
1215
Industry Rank
451
Key Stats
Market Cap
$637.96MUSD
4.32B CNY
Enterprise Value
$602.19MUSD
4.08B CNY
Revenue (TTM)
$229.31MUSD
1.55B CNY
EBITDA (TTM)
$37.08MUSD
250.93M CNY
Net Income (TTM)
$24.38MUSD
165.2M CNY
EBITDA Margin
16%
Profit Margin
11%
PE Ratio
26.1
PS Ratio
2.8
PB Ratio
2.2
EV/EBITDA
15.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Huanxi Cui open_in_new
Employees
1,456
Founded
2002
Website
lifeonapi.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.7% -4.7% -4.9% -15% -20% -12%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
003020
合肥立方制药股份有限公司 Class A
ISIN: CNE100004BD9
Shares Out.:
228.219M1 Shares Float: 222.649M2
TV:
SA:
YF:
GF:
BA:
MS:
22.73 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Hefei Lifeon Pharmaceutical Co., Ltd.

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides intermediate products, such as sodium paeonolsilate, methy2-(2,3-dichlorobenzylidine)-acetoacetate, 3-mercapto-1-propanol, mercaptosuccinic acid and DMPS monohydrate. In addition, it offers nifedipine controlled, doxazosin mesylate, felodipine, trimetazidine dihydrochloride prolonged, and paliperidone release tablets; venlafaxine, methylphenidate, and oxycodone hydrochloride prolonged release tablets; chinese medicines; and proxymetacaine hydrochloride, bendazac lysine, timolol maleate, gatifloxacin, jinzhen, pemirolast potassium, and compound dextran 70 eye drops. Further, it provides paeonol ointment, kecuo yintong gel, compound tujingpi gel, metformin and glipizide tablets, and itraconazole and armillarisin oral solution. The company was incorporated in 2002 and is based in Hefei, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.85B
364.89B CNY
8K%
44.9
603259
$49.64B
336.36B CNY
8K%
17.2
$28.52B
223.48B HKD
4K%
35.7
$18.8B
147.32B HKD
3K%
162.3
$16.51B
111.89B CNY
2K%
-
9926
$16.01B
125.46B HKD
2K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
119K%
38.1
JNJ
$547.28B
86K%
26.4
ABBV
$360.63B
56K%
97.4
$321.52B
256.25B CHF
50K%
19.9
AZN
$288.84B
215.59B GBP
45K%
27.6
NOVN
$274.65B
218.9B CHF
43K%
20.5
chevron_leftBack